OTC coverage
This article was originally published in The Tan Sheet
Executive Summary
The Department of Defense will include OTCs found to be cost effective and therapeutically equivalent to Rx drugs in its formulary as part of a "demonstration project" under the John Warner National Defense Authorization Act For Fiscal Year 2007 (HR 5122), which was presented to the president for signing Oct. 5. DoD's Pharmacy & Therapeutics Committee will determine which OTCs qualify. The program will be implemented no later than May 1, 2007. DoD will evaluate the costs, benefits, clinical effectiveness and customer satisfaction of the program, and provide a report within two years of implementation to the Senate and House Committees on Armed Forces. The report will include proposed improvements and recommendations as to whether the department should have permanent authority to cover OTCs in its pharmacy benefits program...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.